Trial · NCT00633984
D-Cycloserine Enhancement of Exposure in Social Phobia
NCT00633984, Phase 4, Completed, Massachusetts General Hospital; results first posted 2014-05-14
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. D-Cycloserine Enhancement of Exposure in Social Phobia. Trials, record NCT00633984. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00633984
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- D-Cycloserine Enhancement of Exposure in Social Phobia
- NCT number
- NCT00633984
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 169 participants, actual
- Lead sponsor
- Massachusetts General Hospital
- Conditions
- Social Anxiety Disorder
- Interventions
- Cognitive Behavioral Group Therapy (CBGT), D-Cycloserine, Placebo
- First posted
- 2008-03-12
- Last updated
- 2014-05-14
- Results first posted
- 2014-05-14
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Liebowitz Social Anxiety Scale (LSAS) | Week 13 | The Liebowitz Social Anxiety Scale (LSAS) is a 24-item measure designed to assess both fear and avoidance of social and performance situations occurring in the last week. Each item is rated from 0-3 for both fear and avoidance with a possible score of 144; 55-65 Moderate social phobia, 65-80 Marked social phobia, 80-95 Severe social phobia, and Greater than 95 - Very severe social phobia. Remission was defined as a score of \< 30 on the Liebowitz Social Anxiety Scale |
| Primary | CGI - Clinical Global Impression of Improvement | Week 13 | The Clinician Global Impression-Improvement Scale (CGI-I) is a clinician-rated instrument used to assess global severity of symptoms. The CGI-I ranges from 1 ("very much improved") to 7 ("very much worse"). Response and remission was defined as an improvement score of 1 ("very much improved") or 2 ("much improved") on the CGI-I. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Liebowitz Social Anxiety Scale (LSAS) | Week 13 | units on a scale | MEAN | |
| PRIMARY | CGI - Clinical Global Impression of Improvement | Week 13 | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Liebowitz Social Anxiety Scale (LSAS) | Cognitive Behavioral Group Therapy + 50mg D-Cycloserine | 39.19 | 95% Confidence Interval 34.79 to 43.59 | units on a scale | |
| Liebowitz Social Anxiety Scale (LSAS) | Cognitive Behavioral Group Therapy + 50mg Placebo | 42.44 | 95% Confidence Interval 37.94 to 47.03 | units on a scale | |
| CGI - Clinical Global Impression of Improvement | Cognitive Behavioral Group Therapy + 50mg D-Cycloserine | 2.68 | 95% Confidence Interval 2.38 to 2.98 | units on a scale | |
| CGI - Clinical Global Impression of Improvement | Cognitive Behavioral Group Therapy + 50mg Placebo | 2.95 | 95% Confidence Interval 2.64 to 3.27 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cognitive Behavioral Group Therapy + 50mg D-Cycloserine | 87 | |
| Overall Study | STARTED | Cognitive Behavioral Group Therapy + 50mg Placebo | 82 | |
| Overall Study | COMPLETED | Cognitive Behavioral Group Therapy + 50mg D-Cycloserine | 78 | |
| Overall Study | COMPLETED | Cognitive Behavioral Group Therapy + 50mg Placebo | 69 | |
| Overall Study | NOT COMPLETED | Cognitive Behavioral Group Therapy + 50mg D-Cycloserine | 9 | |
| Overall Study | NOT COMPLETED | Cognitive Behavioral Group Therapy + 50mg Placebo | 13 |
Source ClinicalTrials.gov
Adverse events12
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | General | General disorders | Cognitive Behavioral Therapy + DCS | 7 | 87 | |
| other | General | General disorders | Cognitive Behavioral Therapy + Placebo | 4 | 82 | |
| other | Neurological | General disorders | Cognitive Behavioral Therapy + DCS | 6 | 87 | |
| other | Neurological | General disorders | Cognitive Behavioral Therapy + Placebo | 4 | 82 | |
| other | GI | General disorders | Cognitive Behavioral Therapy + DCS | 5 | 87 | |
| other | GI | General disorders | Cognitive Behavioral Therapy + Placebo | 4 | 82 | |
| other | Cognitive/Emotional | General disorders | Cognitive Behavioral Therapy + DCS | 3 | 87 | |
| other | Cognitive/Emotional | General disorders | Cognitive Behavioral Therapy + Placebo | 1 | 82 | |
| other | Genitourinary | General disorders | Cognitive Behavioral Therapy + DCS | 0 | 87 | |
| other | Genitourinary | General disorders | Cognitive Behavioral Therapy + Placebo | 1 | 82 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 adverse eventsAdverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cognitive Behavioral Therapy + DCS | ||
| Total, all-cause mortality | Cognitive Behavioral Therapy + Placebo | ||
| Total, other adverse events | Cognitive Behavioral Therapy + DCS | 26 | 87 |
| Total, other adverse events | Cognitive Behavioral Therapy + Placebo | 19 | 82 |
| Total, serious adverse events | Cognitive Behavioral Therapy + DCS | 0 | 87 |
| Total, serious adverse events | Cognitive Behavioral Therapy + Placebo | 0 | 82 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01MH075889 | D-Cycloserine Enhancement of Exposure in Social Phobia | POLLACK, MARK H | MASSACHUSETTS GENERAL HOSPITAL | NATIONAL INSTITUTE OF MENTAL HEALTH | 2007 to 2010 |
Source NIH RePORTER
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Cognitive Behavioral Therapy + DCS vs Cognitive Behavioral Therapy + Placebo: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00633984
GET https://conductscience.org/api/trials/v1/NCT00633984/registered